A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria:

* Histologically or cytologically documented, incurable, or metastatic solid malignancy that has progressed on or failed to respond to regimens or therapies known to provide clinical benefit

Specific to Arm A:

* For patients undergoing optional or mandatory exploratory MRI, at least one tumor lesion that represents a liver, fixed peritoneal, neck, extremity, or pelvic lesion measuring \>/= 3 to 10 cm (for liver lesions) or \>= 2 to 10 cm (for all other lesion locations) to be used for MRI

Specific to Arm B:

* Maximum of two prior chemotherapy regimens for metastatic disease

Exclusion Criteria:

* Anti-cancer therapy within 3 weeks prior to initiation of study treatment
* Patients who had to discontinue prior bevacizumab therapy due to intolerable toxicity
* Leptomeningeal disease
* Active infection or autoimmune disease
* Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, or cirrhosis
* Known primary central nervous system (CNS) malignancy or untreated or active CNS metastases
* Inadequately controlled hypertension; history of hypertensive crisis or encephalopathy; congestive heart failure (New York Heart Association Class II or greater); history of myocardial infarction or unstable angina within 6 months prior to initiation of study treatment
* History of hemoptysis; evidence of bleeding diathesis or significant coagulopathy
* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to initiation of study treatment
* Serious, non-healing wound, active gastrointestinal ulcer, or untreated bone fracture

Specific to Arm B:

* Known significant hypersensitivity to paclitaxel or other drugs using the vehicle cremophor
* Previous intolerance to paclitaxel
* Grade \>= 2 sensory neuropathy